Rezolute Reports First Quarter Fiscal 2024 Results
- Rezolute, Inc. is on track to commence its Phase 3 study for RZ358 to treat congenital hyperinsulinism, showing promising developments in their clinical trials.
- The company obtained PRIME eligibility from the European Medicines Agency for the treatment of congenital hyperinsulinism, indicating recognition for their novel therapies.
- The financial results for the first quarter of fiscal 2024 showed a total of $106.9 million in cash, cash equivalents, and investments in marketable debt securities.
- None.
REDWOOD CITY, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company committed to developing novel, transformative therapies for serious metabolic and rare diseases, today announced its financial results for the first quarter of fiscal 2024 ended September 30, 2023.
“We are on track to commence our Phase 3 study for RZ358 to treat congenital hyperinsulinism prior to year-end and are delighted to have recently obtained PRIME eligibility from the European Medicines Agency for this indication,” said Nevan Charles Elam, Chief Executive Officer and Founder of Rezolute. “We also anticipate completing enrollment this quarter for our ongoing Phase 2 study of RZ402 for the treatment of diabetic macular edema and plan to provide an update on the study prior to year end.”
Clinical Highlights
- RZ358, a monoclonal antibody for the treatment of hyperinsulinism
- Received EMA priority medicines (PRIME) designation for the treatment of congenital hyperinsulinism (cHI) from the European Medicines Agency
- Plan to initiate sunRIZE, a pivotal Phase 3 clinical study in patients with cHI, in Europe and other geographies outside the US in the fourth quarter 2023
- Continuing the administration of RZ358 in the US with FDA approval under a compassionate use program to treat patients with tumor associated hyperinsulinism, including for a patient with refractory hypoglycemia due to metastatic insulinoma who has remained on RZ358 for nearly a year
- RZ402, an oral plasma kallikrein inhibitor in Phase 2 to treat diabetic macular edema (DME)
- Multi-center, randomized, double-masked, placebo-controlled, parallel-arm study ongoing to evaluate the safety, efficacy, and pharmacokinetics of RZ402 administered as a monotherapy over a 12-week treatment period in participants with DME who are naïve to or have received limited anti-VEGF injections
Study is in the latter stages of patient recruitment and an update on the study will be provided prior to year end
- Multi-center, randomized, double-masked, placebo-controlled, parallel-arm study ongoing to evaluate the safety, efficacy, and pharmacokinetics of RZ402 administered as a monotherapy over a 12-week treatment period in participants with DME who are naïve to or have received limited anti-VEGF injections
First Quarter Fiscal 2024 Financial Results
- Cash, cash equivalents and investments in marketable debt securities totaled
$106.9 million as of September 30, 2023, compared to$118.4 million as of June 30, 2023 - Research and development expenses were
$12.2 million for the first quarter of fiscal 2024, compared to$7.7 million for the same period in fiscal 2023, with the increase primarily attributable to increased expenditures in clinical trial activities, manufacturing costs and higher personnel-related expenses which included employee compensation and stock-based compensation - General and administrative expenses were
$3.7 million for the first quarter of fiscal 2024, compared to$2.5 million for the same period in fiscal 2023, with the increase primarily attributable to higher personnel-related expenses, including employee compensation and stock-based compensation - Net loss was
$14.5 million for the first quarter of fiscal 2024, compared to$9.8 million for the same period in fiscal 2023
About Rezolute, Inc.
Rezolute strives to disrupt current treatment paradigms by developing transformative therapies for devastating rare and chronic metabolic diseases. Its novel therapies hold the potential to both significantly improve outcomes and reduce the treatment burden for patients, treating physicians, and the healthcare system. Rezolute is steadfast in its mission to create profound, positive, and lasting impacts on patients’ lives. Patient, clinician, and advocate voices are integrated in the Company’s drug development process. Rezolute places an emphasis on understanding the patient’s lived experiences, enabling the Company to boldly address a range of severe conditions. For more information, visit www.rezolutebio.com.
Forward-Looking Statements
This release, like many written and oral communications presented by Rezolute and our authorized officers, may contain certain forward-looking statements regarding our prospective performance and strategies within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995 and are including this statement for purposes of said safe harbor provisions. Forward-looking statements, which are based on certain assumptions and describe future plans, strategies, and expectations of Rezolute, are generally identified by use of words such as "anticipate," "believe," "estimate," "expect," "intend," "plan," "project," "seek," "strive," "try," or future or conditional verbs such as "could," "may," "should," "will," "would," or similar expressions. These forward-looking statements include, but are not limited to and statements regarding PRIME designation and the designation’s meaning on the ability of RZ358 to become an effective treatment to congenital HI, the effectiveness or future effectiveness of RZ358 for the treatment of congenital HI, and statements regarding clinical trial timelines for RZ358. Our ability to predict results or the actual effects of our plans or strategies is inherently uncertain. Accordingly, actual results may differ materially from anticipated results. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. Except as required by applicable law or regulation, Rezolute undertakes no obligation to update these forward-looking statements to reflect events or circumstances that occur after the date on which such statements were made. Important factors that may cause such a difference include any other factors discussed in our filings with the SEC, including the Risk Factors contained in the Rezolute’s Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, which are available at the SEC’s website at www.sec.gov. You are urged to consider these factors carefully in evaluating the forward-looking statements in this release and are cautioned not to place undue reliance on such forward-looking statements, which are qualified in their entirety by this cautionary statement.
Investors:
Stephanie Carrington
ICR Westwicke
RezoluteIR@westwicke.com
(646)277-1282
Media:
media-relations@rezolutebio.com
| Rezolute, Inc. | |||||||||||
| Condensed Consolidated Financial Statements Data | |||||||||||
| (in thousands, except per share data) | |||||||||||
| Three Months Ended | |||||||||||
| September 30, | |||||||||||
| 2023 | 2022 | ||||||||||
| Condensed Consolidated Statements of Operations Data: | |||||||||||
| Operating expenses: | |||||||||||
| Research and development | $ | 12,214 | $ | 7,704 | |||||||
| General and administrative | 3,700 | 2,514 | |||||||||
| Total operating expenses | 15,914 | 10,218 | |||||||||
| Loss from operations | (15,914 | ) | (10,218 | ) | |||||||
| Non-operating income (expense), net | 1,390 | 387 | |||||||||
| Net loss | $ | (14,524 | ) | $ | (9,831 | ) | |||||
| Basic and diluted net loss per common share | $ | (0.28 | ) | $ | (0.19 | ) | |||||
| Shares used to compute basic and diluted net loss per common share | 51,409 | 50,528 | |||||||||
| September 30, | June 30, | ||||||||||
| 2023 | 2023 | ||||||||||
| Condensed Consolidated Balance Sheets Data: | |||||||||||
| Cash and cash equivalents | $ | 8,057 | $ | 16,036 | |||||||
| Investments in marketable debt securities | 98,817 | 102,330 | |||||||||
| Working capital | 95,450 | 99,710 | |||||||||
| Total assets | 112,999 | 123,721 | |||||||||
| Accumulated deficit | (275,509 | ) | (260,985 | ) | |||||||
| Total stockholders’ equity | 103,564 | 116,172 | |||||||||
FAQ
What are Rezolute, Inc.'s financial results for the first quarter of fiscal 2024?
What is the Phase 3 study for RZ358?
What is the PRIME eligibility obtained by Rezolute, Inc.?
What is the Phase 2 study of RZ402?
